Journals / Tüberküloz ve Toraks / 2000 / Cilt: 48 - Sayı: 4

Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer

Küçük hücreli dışı akciğer kanserli hastalarda serum intraselüler adezyon molekülü (sICAM-1)

Pages
306–311
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall survival of patients with low ICAM-1 levels tended to be longer than those of patients with high concentrations, although the difference was not significant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recently, abnormal expression of great variety of adhesion molecules has been reported in malignancy.
📊
Key Findings & Data:Intercellular adhesion molecule-1 (ICAM-1) has been suggested to play role in the process of tumour invasion and distant metastasis.
💡
Conclusion & Impact:The overall survival of patients with low ICAM-1 levels tended to be longer than those of patients with high concentrations, although the difference was not significant.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Recently, abnormal expression of great variety of adhesion molecules has been reported in malignancy. Intercellular adhesion molecule-1 (ICAM-1) has been suggested to play role in the process of tumour invasion and distant metastasis. We analysed serum ICAM-1 concentrations by an enzyme-linked immunosorbent assay (ELISA) and investigated the clinical usefullness of these determinations in patient with non-small cell lung cancer (NSCLC). The mean serum concentrations soluble ICAM-1 in 55 patient with NSCLC was 334.76 ± 114.24 whereas it was in 254.15 ± 57.40 healty controls. The differences in mean serum concentrations between control subjects and NSCLC patients were significant (p< 0.01). No difference was observed between histological tumour types, stages and tumour sizes with regard to ICAM-1 levels. The overall survival of patients with low ICAM-1 levels tended to be longer than those of patients with high concentrations, although the difference was not significant. In conclusion our results suggest that the measurement of ICAM-1 in patients with NSCLC may be usefull for serological diagnosis.

Özet

Son yıllarda kanserlerde değişik oranlarda artmış adezyon molekülleri ekspresyonu bildirilmektedir. Serum intraselüler adezyon molekülü ICAM-1'in tümör invazyonu ve metastaz gelişiminde rolü olduğunu gösteren çalışmalar artmaktadır. Biz Küçük hücreli dışı akciğer kanserli (KHDAK) hastalarda serum ICAM-1 konsantrasyonunu ELISA yöntemi ile ölçtük ve klinik değerini araştırdık. Ellibeş KHDAK'li hastada ve 19 sağlıklı kontrol grubunda sICAM-1 düzeyi ölçüldü. Kanserli grupta serum ICAM-1 ortalama değeri 334.76 ± 114.24 ölçülürken, kontrol grubunda 254.15 ± 57.40 bulundu (p< 0.01). Akciğer kanserinin histolojik tipleri ile sICAM-1 düzeyi arasında anlamlı korelasyon saptandı. Hastalığın evresi ve tümör çapı ile istatistiksel fark gösterilmedi. Serum ICAM-1 düzeyi yüksek olanlarda yaşam süresi daha kısa olsa da aradaki fark istatistiksel olarak anlamlı çıkmadı. Bizim sonuçlarımıza göre KHDAK'de serum ICAM-1 ölçümü hastalığın serolojik tanısında kullanılabilir.

🔖

Cite This Article

KAYA, A., GÖNÜLLÜ, U., SAVAŞ, İ., GÜRKAN, Ö. U., ERİŞ, B. (2022). Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer. Tüberküloz ve Toraks, Cilt: 48 - Sayı: 4, 306–311. https://ajindex.com/articles/619478

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Frenette PS, WagnerDD. Adhesion molecules-part I. New Engl J Med 1996; 334:1526-29
  2. Frenette PS, Wagner DD. Adhesion molecules- Part II.New Engl J Med 1996; 335: 43-5
  3. Laffon A, Gonzales-Amaro R. Cell adhesion molecules. An overview. Br J Rheumatol 1995;34: 1101-4
  4. Albelda SM. Biology of disease. Role ofintegrlns and other adhesion molecules in tumor progreslon and metastasis. Lab Inuest 1993; 68: 4-17
  5. Pauli BU, Augustin-Voss HG, El-sabban ME, Johnson RC, Hammer DA. Organ preference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Reu 1990; 9:175-89, 6. Ishii Y, Kitamura S. Soluble Intercellular adhesion molecule-1 as an early detection marker for radiation pneumonltis. Eur Respir J 1999; 13: 733-8
  6. Harning R, Mainolfi E, Bystryn JC, et at. Serum leuels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 1991; 51:5003-5
  7. Christiansen I, Gidlof C, Kalkner KM, et al. Elevated serum leuels of soluble ICAM-1 In non-Hodgkin's lymphomas correlate with tumour burden, disease actiuity and other prognostic markers. Br J Haematol 1996; 92: 639-46
  8. Christiansen I, Gidlof C, Wallgren AC, et al. Serum leuels of soluble Intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 1994; 84:3010-6
  9. Christiansen I, Enblad G, Kalkner KM, et at Soluble ICAM-1 in Hodgkin's disease: A promising independent predictive marker for survival. Leuk Lymphoma 1995; 19: 3129-39
  10. Gruss HJ, Dolken G, Brach MA, et al. Serum levels of circulating ICAM'1 are increased in Hodgkin's disease. Leukemia 1993; 7: 1245
  11. Tsujisaki M, Imai K, Hirata H, et at Detection of 1 (ICAM-1) during the development of Invasion an carcinoma. J Cancer Res Clin Oncol 1992; 18: 609-61
  12. Banks RE, Gearing AJH, Hemingway IK, et at Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular cell adhesion molecule 1 (VCAM-İ) In human malignancies. Br J Cancer 1993; 68: 122-4
  13. Sprenger A, Schardt C, Rotsch M, et al. Soluble Intercellular adhesion molecule-1 in patients with lung cancer and benign lung diseases. J Cancer Res Clin Oncol 1997; 123: 632-8
  14. Tauchl O, Gabazza EC, Kobayashi T, et al. Circulating intercellular adhesion molecule-1in patients with lung cancer. Intern Med 1997; 36: 14-8
  15. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility classl and Class II ant